Whitepapers

GLP-1 receptor agonists have substantially reshaped the therapeutic landscape for type 2 diabetes and obesity, and the...

Drug development for chronic kidney disease has entered a more ambitious phase. SGLT2 inhibitors, non steroidal...

Chemotherapy induced peripheral neuropathy remains one of the most underserved symptoms in oncology supportive care....

Chronic wounds in diabetic patients are one of the costliest quietly growing burdens in medicine. Roughly 15 to 25...

Stroke remains one of the highest attrition areas in drug development. Despite decades of preclinical programs showing...